{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T08:25:29Z","timestamp":1766305529157},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T00:00:00Z","timestamp":1338249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T00:00:00Z","timestamp":1338249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/tpj.2012.19","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T10:07:49Z","timestamp":1338286069000},"page":"359-361","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms"],"prefix":"10.1038","volume":"13","author":[{"given":"P","family":"Dorado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"L\u00f3pez-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E M","family":"Pe\u00f1as-LLed\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Mart\u00ednez-Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"LLerena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,29]]},"reference":[{"key":"BFtpj201219_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0009-9236(97)90031-X","volume":"62","author":"A Odani","year":"1997","unstructured":"Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62: 287\u2013292.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201219_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","volume":"52","author":"JA Goldstein","year":"2001","unstructured":"Goldstein JA . Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349\u2013355.","journal-title":"Br J Clin Pharmacol"},{"key":"BFtpj201219_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00228-003-0588-0","volume":"59","author":"P Dorado","year":"2003","unstructured":"Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, LLerena A . CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003; 59: 221\u2013225.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201219_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00008571-200106000-00002","volume":"11","author":"J Van der Weide","year":"2001","unstructured":"Van der Weide J, Steijns LSW, van Weelden MJM, de Haan K . The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11: 287\u2013291.","journal-title":"Pharmacogenetics"},{"key":"BFtpj201219_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","volume":"69","author":"A Li-Wan-Po","year":"2010","unstructured":"Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J . Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010; 69: 222\u2013230.","journal-title":"Br J Clin Pharmacol"},{"key":"BFtpj201219_CR6","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1528-1157.1998.tb01330.x","volume":"39","author":"K Mamiya","year":"1998","unstructured":"Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998; 39: 1317\u20131323.","journal-title":"Epilepsia"},{"key":"BFtpj201219_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0009-9236(97)90031-X","volume":"62","author":"A Odani","year":"1997","unstructured":"Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62: 287\u2013292.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201219_CR8","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","volume":"55","author":"C Luna-Tort\u00f3s","year":"2008","unstructured":"Luna-Tort\u00f3s C, Fedrowitz M, L\u00f6scher W . Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008; 55: 1364\u20131375.","journal-title":"Neuropharmacology"},{"key":"BFtpj201219_CR9","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1056\/NEJMoa021986","volume":"348","author":"A Siddiqui","year":"2003","unstructured":"Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. NEJM 2003; 348: 1442\u20131448.","journal-title":"NEJM"},{"key":"BFtpj201219_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/FPC.0b013e3282f85e36","volume":"18","author":"CC Hung","year":"2008","unstructured":"Hung CC, Chen CC, Lin CJ, Liou HH . Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics 2008; 18: 390\u2013402.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201219_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/sj.tpj.6500025","volume":"1","author":"R Kerb","year":"2001","unstructured":"Kerb R, Aynacioglu AS, Brockm\u00f6ller J, Schlagenhaufer R, Bauer S, Szekeres T et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for Phenytoin plasma levels. Pharmacogenomics J 2001; 1: 204\u2013210.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201219_CR12","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1177\/0091270009343006","volume":"49","author":"S Hennessy","year":"2009","unstructured":"Hennessy S, Leonard CE, Freeman CP, Metlay JP, Chu X, Strom BL et al. CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol 2009; 49: 1483\u20131487.","journal-title":"J Clin Pharmacol"},{"key":"BFtpj201219_CR13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0009-9236(01)95478-5","volume":"70","author":"R Brandolese","year":"2001","unstructured":"Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R . Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70: 391\u2013394.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201219_CR14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1212\/01.WNL.0000058756.61277.17","volume":"60","author":"G Criterio","year":"2003","unstructured":"Criterio G, Nobili A, Airoldi L, Pastorelli R, Patruno A . Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. Neurology 2003; 60: 1395\u20131396.","journal-title":"Neurology"},{"key":"BFtpj201219_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4103\/0028-3886.33300","volume":"55","author":"K Ramasamy","year":"2007","unstructured":"Ramasamy K, Narayan SK, Chanolean S, Chandrasekaran A . Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India. Neurol India 2007; 55: 408\u2013409.","journal-title":"Neurol India"},{"key":"BFtpj201219_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12028-008-9165-9","volume":"10","author":"LK McCluggage","year":"2009","unstructured":"McCluggage LK, Voils SA, Bullock MR . Phenytoin toxicity due to genetic polymorphism. Neurocrit Care 2009; 10: 222\u2013224.","journal-title":"Neurocrit Care"},{"key":"BFtpj201219_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00228-010-0817-2","volume":"66","author":"R Kesavan","year":"2010","unstructured":"Kesavan R, Narayan SK, Adithan C . Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol 2010; 66: 689\u2013696.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201219_CR18","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1073\/pnas.0407346102","volume":"102","author":"SK Tate","year":"2005","unstructured":"Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005; 102: 5507\u20135512.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201219_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0378-4347(93)80477-L","volume":"616","author":"H Liu","year":"1993","unstructured":"Liu H, Delgado M, Forman LJ, Eggers CM, Montoya JL . Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. J Chromatogr 1993; 616: 105\u2013115.","journal-title":"J Chromatogr"},{"key":"BFtpj201219_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00007691-200004000-00016","volume":"22","author":"H Ninomiya","year":"2000","unstructured":"Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N . Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000; 22: 230\u2013232.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201219_CR21","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473\u20133478.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201219_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1365-2125.1981.tb01285.x","volume":"12","author":"PG Blain","year":"1981","unstructured":"Blain PG, Mucklow JC, Bacon CJ, Rawlins MD . Pharmacokinetics of phenytoin in children. Br J Clin Pharmacol 1981; 12: 659\u2013661.","journal-title":"Br J Clin Pharmacol"},{"key":"BFtpj201219_CR23","first-page":"455","volume":"3","author":"N Gerber","year":"1972","unstructured":"Gerber N, Wagner JG . Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Res Commun Chem Pathol Pharmacol 1972; 3: 455\u2013466.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"BFtpj201219_CR24","first-page":"532","volume":"51","author":"DP Soskin","year":"2010","unstructured":"Soskin DP, Kane AJ, Stern TA . Phenytoin toxicity secondary to an oxcarbazepine-phenytoin 2C19 interaction. Psychosomatics 2010; 51: 532\u2013535.","journal-title":"Psychosomatics"},{"key":"BFtpj201219_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0009-9236(03)00124-3","volume":"74","author":"WM Sallas","year":"2003","unstructured":"Sallas WM, Milosavljev S, D'souza J, Hossain M . Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther 2003; 74: 138\u2013149.","journal-title":"Clin Pharmacol Ther"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201219","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T21:14:43Z","timestamp":1713993283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,29]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFtpj201219"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2012.19","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,29]]},"assertion":[{"value":"22 November 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}